[On the effects of L-dopa in man and their modification by reserpine, chlorpromazine, iproniazid and vitamin B6] - PubMed (original) (raw)

[On the effects of L-dopa in man and their modification by reserpine, chlorpromazine, iproniazid and vitamin B6]

[Article in German]

R DEGKWITZ et al. Klin Wochenschr. 1960.

No abstract available

PubMed Disclaimer

Similar articles

• Abolition by chlorpromazine of the inhibiting effect of iproniazid on the depletion of adrenal catechol amines induced by reserpine.
  CAMANNI F, MOLINATTI GM, OLIVETTI M. CAMANNI F, et al. Nature. 1959 Sep 5;184:65-6. Nature. 1959. PMID: 13848162 No abstract available.
• Antagonism of locomotor suppressant effects of reserpine in mice.
  SMITH CB, DEWS PB. SMITH CB, et al. Psychopharmacologia. 1962 Mar 12;3:55-9. doi: 10.1007/BF00413107. Psychopharmacologia. 1962. PMID: 13914163 No abstract available.
• Evidence for a direct action of monamines on the chick central nervous system.
  Spooner CE, Winters WD. Spooner CE, et al. Experientia. 1965 May 15;21(5):256-8. doi: 10.1007/BF02297010. Experientia. 1965. PMID: 5294557 No abstract available.
• [PSYCHOPHARMACA: OBSERVATIONS AND INTERPRETATIONS].
  DESCHAEPDRYVER A. DESCHAEPDRYVER A. Belg Tijdschr Geneesk. 1964 Dec 15;20:1265-76. Belg Tijdschr Geneesk. 1964. PMID: 14261099 Review. Dutch. No abstract available.
• The effect of neuropharmacological agents on metabolism in vitamin B6 in brain.
  McCoy EE, Henn SW, Colombini CE. McCoy EE, et al. Adv Biochem Psychopharmacol. 1972;4:93-104. Adv Biochem Psychopharmacol. 1972. PMID: 4557808 Review. No abstract available.

Cited by

• [Biochemical aspects of the effect of L-dopa in patients with Parkinson's disease].
  Gründig E, Gerstenbrand F, Oberhummer J, Simanyi M, Schedl R, Weiss J. Gründig E, et al. Z Neurol. 1972;203(1):73-90. Z Neurol. 1972. PMID: 4118094 German. No abstract available.
• Parkinson's disease, dopaminergic drugs and the plant world.
  Kempster P, Ma A. Kempster P, et al. Front Pharmacol. 2022 Sep 5;13:970714. doi: 10.3389/fphar.2022.970714. eCollection 2022. Front Pharmacol. 2022. PMID: 36133818 Free PMC article. Review.
• [ADDITIONAL EXPERIMENTAL STUDIES ON L-DOPA IN PARKINSON'S SYNDROME AND RESERPINE PARKINSONISM].
  BIRKMAYER W, HORNYKIEWICZ O. BIRKMAYER W, et al. Arch Psychiatr Nervenkr. 1964 Dec 2;206:367-81. doi: 10.1007/BF00341704. Arch Psychiatr Nervenkr. 1964. PMID: 14345318 German. No abstract available.
• Monoamine oxidase inhibitors and L-dopa.
  Hunter KR, Boakes AJ, Laurence DR, Stern GM. Hunter KR, et al. Br Med J. 1970 Aug 15;3(5719):388. doi: 10.1136/bmj.3.5719.388. Br Med J. 1970. PMID: 5451592 Free PMC article. No abstract available.
• [THE EFFICACY OF L-DOPA IN PARKINSON PATIENTS WITH AND WITHOUT STEREOTACTIC BRAIN SURGERY].
  UMBACH W, BAUMANN D. UMBACH W, et al. Arch Psychiatr Nervenkr. 1964 Jun 1;205:281-92. doi: 10.1007/BF00395715. Arch Psychiatr Nervenkr. 1964. PMID: 14175212 German. No abstract available.

References

1. 1. Nature. 1957 Nov 30;180(4596):1200 - PubMed
2. 1. J Pharmacol Exp Ther. 1956 Jun;117(2):213-27 - PubMed
3. 1. J Clin Exp Psychopathol. 1958 Apr-Jun;19(2, Suppl. 1):61-8; discussion 68-71 - PubMed
4. 1. Lancet. 1954 Sep 18;267(6838):570-2 - PubMed
5. 1. Schweiz Med Wochenschr. 1953 Oct 17;83(42):1007-12 - PubMed

MeSH terms

Substances